Clinical trial
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in…
NCT00193531 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193531 |
|---|---|
| Title | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma |
| Official title | Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Carcinoma |
| Intervention type | Drug |
| Interventions | Paclitaxel, Carboplatin, Etoposide |
| Enrollment | 100 |
| Start date | Dec 1, 1998 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Apr 11, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: